Kristin Speer, PharmD, BCPS, RPh

Emerging evidence supports the use of psilocybin in palliative care, yet Schedule I status uniquely limits access outside of clinical trials in the US.

Engagement and recognition of pharmacist expertise grows as state psychedelic bills expand.